Blog

Motivated patients are more likely to have better adherence and outcomes. Healthcare providers (HCPs) and families play crucial roles in treatment. Cancer mortality has significantly dropped over time, but nonadherence continues to be a problem. This is particularly so for patients taking oral oncolytics.

Measuring success in any endeavor requires a metric and scale by which to measure. Once this is determined, a method must be developed to determine how a company’s efforts rate.

Biopharma companies offer many forms of support when therapy is initiated. Substantial research indicates people with rare or complex conditions require a more intensive level of support that includes addressing the emotional needs related to their condition.

Biopharma utilizes behavioral science more than ever to understand patients, personalize engagement, and motivate therapy adherence.

The pharmaceutical industry continues to make a clear commitment to pharma patient engagement, and the total market investment is expected to increase more than 15% by 2030, according to Grand View Research.

Imagine losing your freedom daily. Dealing with the inability to leave your house in the morning. Missing out on birthdays, recitals, and family vacations... This is how 3.1 million adults in the US live every single day.

There are many opportunities for the biopharma industry to improve patients’ therapy journey and overall care.

In our September Patient Services Report, Momentum Life Sciences discussed the single-point-of-contact (SPOC) model for patient engagement programs in the biopharma industry and what makes this such an effective way to enhance the patient experience, boost outcomes, and increase efficiencies for our clients.